Stocksigma LogoStocksigma Logo

Evonile Pharma Reports Q2 FY27 Financial Results and Business Model Transition

Evonile Pharma transitioned to an independent domestic model, establishing 20+ CFAs and 2,000+ stockists

Evonile Pharma Reports Q2 FY27 Financial Results and Business Model Transition

Novartis India Ltd · Investor Presentation · 04 Nov 2026, 1:14 am

Evonile Pharma Reports Q2 FY27 Financial Results and Business Model Transition Evonile Pharma transitioned to an independent domestic model, establishing 20+ CFAs and 2,000+ stockists. Q2 FY27 revenue from operations declined 38% YoY to ₹56.1 cr from ₹90.3 cr in Q2 FY26 due to the business model shift. Operating EBITDA was -₹31.8 cr with a net loss of ₹77.5 cr, impacted by ₹15.4 cr in one-off transition expenses and ₹68.3 cr in exceptional items from promotion rights termination. H1 FY27 revenue stood at ₹159.9 cr with a ₹45.3 cr net loss.

Original exchange filing (PDF)

More announcements from Novartis India Ltd

All Novartis India Ltd announcements